Molecular imaging of neuroendocrine tumours optimises radiotherapy dose

Aggressive neuroendocrine cancer is something of a dark horse – a rare, elusive and persevering force linked to discouraging long-term survival rates. Researchers at the 2016 Annual Meeting of the Society of Nuclear Medicine and Molecular Imaging are presenting a molecular imaging technique that allows oncologists to set patients’ radiotherapy doses right at that critical limit of delivering the most powerful kill to neuroendocrine tumours while protecting vulnerable vital organs.
Science Daily